Back to the list
Congress: ECR24
Poster Number: C-16702
Type: EPOS Radiologist (scientific)
Authorblock: S. Gruendemann, F. Kreis, P. Severin, G. Jost, J. Lohrke, H. Pietsch; Berlin/DE
Disclosures:
Stephan Gruendemann: Employee: Bayer AG
Felix Kreis: Employee: Bayer AG
Philipp Severin: Employee: Bayer AG
Gregor Jost: Employee: Bayer AG
Jessica Lohrke: Employee: Bayer AG
Hubertus Pietsch: Employee: Bayer AG
Keywords: Contrast agents, MR, Contrast agent-intravenous, Physics, Safety, Toxicity
References
  1. Lohrke, J., et al., 25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives. Adv Ther, 2016. 33(1): p. 1-28.
  2. Endrikat, J., et al., Safety of Gadobutrol: Results From 42 Clinical Phase II to IV Studies and Postmarketing Surveillance After 29 Million Applications. Invest Radiol, 2016. 51(9): p. 537-43.
  3. de Kerviler, E., et al., Adverse Reactions to Gadoterate Meglumine Review of Over 25 Years of Clinical Use and More Than 50 Million Doses. Investigative Radiology, 2016. 51(9): p. 544-551.
  4. Morgan, D.E., et al., Assessment of Adverse Reaction Rates during Gadoteridol-enhanced MR Imaging in 28 078 Patients. Radiology, 2011. 259(1): p. 109-116.
  5. Grobner, T., Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant, 2006. 21(4): p. 1104-8.
  6. Kanda, T., et al., High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology, 2014. 270(3): p. 834-41.
  7. Errante, Y., et al., Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol, 2014. 49(10): p. 685-90.
  8. Frenzel, T., et al., Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37 degrees C. Investigative Radiology, 2008. 43(12): p. 817-828.
  9. Wahsner, J., et al., Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers. Chem Rev, 2019. 119(2): p. 957-1057.
  10. Hao, D., et al., MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging, 2012. 36(5): p. 1060-71.
  11. Lohrke, J., et al., Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents. Invest Radiol, 2017. 52(6): p. 324-333.
  12. Rasschaert, M., et al., Gadolinium Retention, Brain T1 Hyperintensity, and Endogenous Metals: A Comparative Study of Macrocyclic Versus Linear Gadolinium Chelates in Renally Sensitized Rats. Invest Radiol, 2018. 53(6): p. 328-337.
  13. Radbruch, A., et al., Gadolinium Retention in the Dentate Nucleus and Globus Pallidus Is Dependent on the Class of Contrast Agent. Radiology, 2015. 275(3): p. 783-791.
  14. Runge VM, Heverhagen JT. Advocating the development of next-generation high-relaxivity gadolinium chelates for clinical magnetic resonance. Invest Radiol. 2018; 53:381–389.
  15. Robic C., et al., Physicochemical and Pharmacokinetic Profiles of Gadopiclenol. A New Macrocyclic Gadolinium Chelate With High T1 Relaxivity. Invest Radiol, 2019. 54(8): p. 475-484.
  16. Hao J., et al., A Comprehensive Overview of the Efficacy and Safety of Gadopiclenol: A New Contrast Agent for MRI of the CNS and Body. Invest Radiol, 2024. 59: p. 124-130.
  17. Lohrke, J., et al., Preclinical Profile of Gadoquatrane. A Novel Tetrameric, Macrocyclic High Relaxivity Gadolinium-Based Contrast Agent. Invest Radiol, 2022. 57(10): p. 629-638.
  18. Hofmann, B. M., et al., Pharmacokinetics, Safety, and Tolerability of the Novel Tetrameric,High-Relaxivity, Macrocyclic Gadolinium-Based Contrast Agent Gadoquatrane in Healthy Adults. Invest Radiol, 2024. 59: p. 140-149.
  19. Szomolanyi, P., et al., Comparison of the Relaxivities of Macrocyclic Gadolinium-Based Contrast Agents in Human Plasma at 1.5, 3, and 7 T, and Blood at 3 T. Invest Radiol, 2019. 54(9): p. 559-564.
  20. Port, M., et al., Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals, 2008. 21(4): p. 469-490.
GALLERY